<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424175</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002475</org_study_id>
    <nct_id>NCT02424175</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.</brief_title>
  <official_title>Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label single-arm pilot study to measure the safety, microbiological and&#xD;
      clinical impacts of Fecal Microbiota Transplantation (FMT) in patients with Primary&#xD;
      Sclerosing Cholangitis (PSC). The investigators will prospectively enroll 10 PSC patients&#xD;
      Stage 1 and 2 who also have concurrent inflammatory bowel disease Donor Stool from one&#xD;
      healthy donor will be obtained from OpenBiome. OpenBiome is a nonprofit 501(c)(3)&#xD;
      organization that provides hospitals with screened, filtered, and frozen material ready for&#xD;
      clinical use&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Significance:&#xD;
&#xD;
      Primary sclerosing cholangitis (PSC) is a progressive, chronic cholestatic liver disease&#xD;
      characterized by inflammatory and fibrotic destruction of the intrahepatic and/or&#xD;
      extrahepatic bile ducts. PSC will progress to biliary cirrhosis, portal hypertension and&#xD;
      liver failure (1) . It is a common indication for liver transplantation. In up to 90% of&#xD;
      patients, ulcerative colitis or Crohn's disease will also be present (2) . Medications used&#xD;
      for the treatment of ulcerative colitis such as sulfasalazine, corticosteroids and&#xD;
      azathioprine or 6-mercaptopurine have not been effective in reducing inflammation or bringing&#xD;
      about remission in PSC (3) . A number of studies of other anti-inflammatory agents have&#xD;
      failed to demonstrate any benefit. In standard dosing, ursodeoxycholic acid (UDCA) may be of&#xD;
      benefit in delaying the progression of disease, although a recent study showed that high dose&#xD;
      UDCA was not only ineffective, it may also be harmful (4) . Currently there is no medical&#xD;
      therapy that has been shown to be effective in PSC and no therapy has won FDA approval for&#xD;
      this indication.&#xD;
&#xD;
      It has been postulated that bacterial components may stimulate an aberrant immune response&#xD;
      resulting in the perpetuation of the biliary inflammation seen in PSC. Bacteria gain access&#xD;
      to the liver and biliary tree through translocation across an abnormal and inflamed&#xD;
      intestinal mucosa into the portal venous system (5) . Studies have shown an increased risk of&#xD;
      portal venous bacteremia in patients with PSC. Animal models have demonstrated that enteric&#xD;
      dysbiosis can lead to hepatobiliary inflammation with various features of PSC (6) . The&#xD;
      pathways through which bacteria might then induce the pathology characteristic of PSC are&#xD;
      speculative.&#xD;
&#xD;
      Bacteria might cause direct injury through colonization, though studies have not identified&#xD;
      any particular pathogen or a consistent set of bacteria. Another potential pathway may be&#xD;
      that a certain set of bacteria generate secondary bile acids, such as deoxycholic acid and&#xD;
      lithocholic acid, which are injurious to the biliary system (7) . We recently found an&#xD;
      altered serum bile acid composition in patients with PSC compared to non-cholestatic&#xD;
      controls. Treatment with UDCA in PSC patients decreases the concentration of the toxic&#xD;
      primary bile acid chenodeoxycholic acid but also increased the toxic secondary bile acid&#xD;
      lithocholic acid (Abstract DDW 2014). Alteration of the gut microbiota may minimize or&#xD;
      eliminate this injury.&#xD;
&#xD;
      There is limited experience in the use of antibiotics in treating PSC. Metronidazole has been&#xD;
      shown to result in improvement in liver function tests (8) . Oral vancomycin has also been&#xD;
      advanced as a potentially promising therapy (9) . An initial report of three pediatric&#xD;
      patients and a subsequent small, uncontrolled series of oral vancomycin in 14 children showed&#xD;
      improvement in liver tests and symptoms (10, 11) . We recently completed a study of oral&#xD;
      vancomycin was given to 10 adults with PSC found mild improvement in serum alkaline&#xD;
      phosphatase levels (Abstract DDW 2011).&#xD;
&#xD;
      Fecal Biotherapy (FBT) also known as fecal transplantation or fecal microbiota&#xD;
      transplant-involves the transfer of a donor's fecal flora (bacteria) to a recipient's colon.&#xD;
      It has become widely accepted as the standard of care for recurrent Clostridium difficile 3&#xD;
      infection, with a cumulative cure rate of &gt;90% and minimal adverse events (12) . In C. diff&#xD;
      infection, prior exposure to antibiotics diminishes the normal colonic flora, allowing C.&#xD;
      diff organism to proliferate and release toxin (13) . This bacterial environment is similar&#xD;
      to the major shifts in microbial diversity seen in patients with IBD. Interestingly, when&#xD;
      patients with IBD receive FBT for C. diff. infections, their outcomes are excellent,&#xD;
      reinforcing the notion that the enteric flora have a strong influence in the enteric immune&#xD;
      system (14) . We currently have a robust FMT clinical program for recurrent and refractory&#xD;
      c.difficle infections with a cure rate &gt; 90%. We have also recently participated in an open&#xD;
      label clinical trial for the use of FMT in crohn's disease.&#xD;
&#xD;
      We hypothesize that for patients with PSC, fecal microbiota transplantation will correct a&#xD;
      dysbiosis that has led to hepatobiliary inflammation leading to improvement in LFTs and slow&#xD;
      progression to cirrhosis.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      Specific Aim 1: Determine the impact of fecal microbiota transplantation on the intestinal&#xD;
      microbiome of patients with primary sclerosis cholangitis with and without inflammatory bowel&#xD;
      disease via 16s ribosomal RNA sequencing comparing delivery modalities (colonoscopy and&#xD;
      capsules).&#xD;
&#xD;
      Hypothesis: Fecal microbiota transplantation will result in a sustained repopulation of the&#xD;
      patient's microbiome that corresponds to the bacteria from the donor stool.&#xD;
&#xD;
      Specific Aim 2: Assess for clinical response in patients with PSC receiving FMT comparing&#xD;
      delivery modalities (colonoscopy and capsules).&#xD;
&#xD;
      Hypothesis: Fecal microbiota transplantation will lead to a 50% reduction in liver&#xD;
      biochemistries in patients with PSC.&#xD;
&#xD;
      Specific Aim 3: Assess bile salt metabolomics as a therapeutic biomarker for clinical&#xD;
      response to fecal microbiota transplantation.&#xD;
&#xD;
      Hypothesis: A decrease in the production of toxic secondary bile acids (lithocholic and&#xD;
      deoxycholic acid) will correlate with clinical response to fecal microbiota therapy&#xD;
&#xD;
      Primary Physiological Endpoint:&#xD;
&#xD;
      12&#xD;
&#xD;
      1. Recipient's fecal microbial diversity at 12 weeks after FMT, when compared to baseline&#xD;
      using 16s ribosomal RNA.&#xD;
&#xD;
      Primary Clinical Endpoint&#xD;
&#xD;
      1. The primary study end point is them mean change serum liver biochemistries after 3 months&#xD;
      of treatment as compared with baseline. Treatment success was defined as an improvement in&#xD;
      serum alkaline phosphatase, total bilirubin, alanine aminotransferase (ALT), or aspartate&#xD;
      aminotransferase (AST) by 50 % or greater.&#xD;
&#xD;
      Secondary Endpoints Metabolomics: Bile salt profiles of the samples and associated community&#xD;
      structure of the fecal microbiome will be assessed as a measure of the interplay between host&#xD;
      and gut microbiota. Stool and Serum will be analyzed using the metabolomics platform at the&#xD;
      Broad Institute, targeting bile acids. Samples will be sent to the Broad Institute where we&#xD;
      will use liquid chromatography tandem mass spectrometry (LC-MS) to measure endogenous bile&#xD;
      salts and their metabolite levels in fecal supernatant. Water soluble metabolites will be&#xD;
      extracted from feces as described by Saric et al while lipids will be extracted from&#xD;
      lypophilized samples using isopropanol. Water soluble metabolites will be measured using ion&#xD;
      pairing chromatography and hydrophilic interaction chromatography methods, and lipids and&#xD;
      bile acids will be measured using C4 and C18 reversed phase chromatography methods.&#xD;
      MultiQuant software (AB SCIEX) will be used for automated peak integration and manual review&#xD;
      of peak quality prior to statistical analyses. The GenePattern (Broad Institute) and IPA&#xD;
      (Ingenuity Systems) software will be used to analyze and visualize results.&#xD;
&#xD;
      Clinical Endpoints:&#xD;
&#xD;
        1. Mean change in Harvey Bradshaw Index (HBI) and PBC 40 score between week 0 and week 1,&#xD;
           4, 8, and 12. Percentage of patients in clinical remission (those with an HBI score at&#xD;
           week 12 &lt;5)&#xD;
&#xD;
        2. Mean change in Mayo Risk Score at week 12 compared to baseline. The Mayo Risk Score&#xD;
           (MRS) for PSC is calculated based using the following formula: risk = (0.0295 * (age in&#xD;
           years)) + (0.5373 * LN(total bilirubin in mg/dL)) - (0.8389 * (serum albumin in g/dL)) +&#xD;
           (0.5380 * LN(AST in IU/L) + (1.2426 * (points for variceal bleeding)) If your Mayo Risk&#xD;
           Score is less than or equal to 0 then you are in the &quot;low&quot; risk group. If your Mayo Risk&#xD;
           Score is greater than 0 but less than 2 then you are in the &quot;intermediate&quot; risk group.&#xD;
           If your Mayo Risk Score is greater than 2 then you are in the &quot;high&quot; risk group.&#xD;
&#xD;
      Safety Endpoints: Number and nature of adverse events at week 1, 4, 8, 12 and 24&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">May 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with reporting adverse events irregardless of severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Alkaline Phosphatase Pre and Post Transplant</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The primary clinical study end point is the number of patients that achieve a 50% or more decrease serum alkaline phosphatase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients that experienced changes in the microbiome post FMT. Measured as similarity to the donor microbiome post FMT compared to their baseline sample</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Patients with PSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <arm_group_label>Patients with PSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or older&#xD;
&#xD;
          2. Confirmed diagnosis of PSC (with a concurrent diagnosis of inflammatory bowel disease)&#xD;
             characterized by a cholestatic liver condition of greater than 6 months duration with&#xD;
             confirmatory cholangiographic findings, as well as an elevation of the serum alkaline&#xD;
             phosphatase of greater than 1.5 times the upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver disease&#xD;
&#xD;
          2. Patients who were pregnant or breastfeeding&#xD;
&#xD;
          3. Use of concomitant immune modulators including methotrexate, mycophenolate mofetil,&#xD;
             tacrolimus, cyclosporine, thalidomide, Interleukin-10, or Interleukin-11 within 4&#xD;
             weeks prior to receiving the FMT&#xD;
&#xD;
          4. Patients who are unable to give informed consent&#xD;
&#xD;
          5. Patients who are unable or unwilling to undergo colonoscopy with moderate sedation&#xD;
             (&gt;ASA class II)&#xD;
&#xD;
          6. Patients who have previously undergone FMT Patients who have a confirmed malignancy or&#xD;
             cancer&#xD;
&#xD;
          7. Patients who are immunocompromised&#xD;
&#xD;
          8. Treatment within last 8 weeks with infliximab, adalimumab, certolizumab, natalizumab,&#xD;
             vedolizumab or thalidomide&#xD;
&#xD;
          9. Antibiotic use within 2-months of start date&#xD;
&#xD;
         10. Participation in a clinical trial in the preceding 30 days or simultaneously during&#xD;
             this trial&#xD;
&#xD;
         11. Probiotic use within 30 days of start date&#xD;
&#xD;
         12. Congenital or acquired immunodeficiencies&#xD;
&#xD;
         13. Other comorbidities including:Diabetes mellitus, cancer, systemic lupus, must be able&#xD;
             to tolerate conscious sedation with colonoscopy&#xD;
&#xD;
         14. Chronic kidney disease as defined by a GFR &lt;60mL/min/1.73m2 44&#xD;
&#xD;
         15. History of rheumatic heart disease, endocarditis, or valvular disease due to risk of&#xD;
             bacteremia from colonoscopy&#xD;
&#xD;
         16. Steroid dose &gt;20mg/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Korzenik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 18, 2015</study_first_submitted>
  <study_first_submitted_qc>April 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>July 7, 2019</results_first_submitted>
  <results_first_submitted_qc>July 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joshua Korzenik</investigator_full_name>
    <investigator_title>Director, Crohn's and Colitis Center</investigator_title>
  </responsible_party>
  <keyword>Fecal Transplant</keyword>
  <keyword>Primary Sclerosing Cholangitis</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02424175/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study lasted from February 2016 until June 2017. 10 total patients were recruited through the Brigham and Women's Hospital Gastroenterology clinic and through referrals from other Gastroenterologists.</recruitment_details>
      <pre_assignment_details>A wash out period was included for patients. All subjects should not have used antibiotics within 2 months of start date or receive treatment of infliximab, adalimumab, certolizumab, natalizumab, vedolizumab or thalidomide within the past 8 weeks. They are also screened for various infectious risks such as HIV or Hepatitis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With PSC</title>
          <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With PSC</title>
          <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" lower_limit="23" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline phosphatase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="489" lower_limit="111" upper_limit="1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150.7" lower_limit="74" upper_limit="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.4" lower_limit="60" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event Frequency</title>
        <description>Number of patients with reporting adverse events irregardless of severity</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With PSC</title>
            <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Frequency</title>
          <description>Number of patients with reporting adverse events irregardless of severity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Alkaline Phosphatase Pre and Post Transplant</title>
        <description>The primary clinical study end point is the number of patients that achieve a 50% or more decrease serum alkaline phosphatase</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With PSC</title>
            <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Alkaline Phosphatase Pre and Post Transplant</title>
          <description>The primary clinical study end point is the number of patients that achieve a 50% or more decrease serum alkaline phosphatase</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiome</title>
        <description>Number of patients that experienced changes in the microbiome post FMT. Measured as similarity to the donor microbiome post FMT compared to their baseline sample</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With PSC</title>
            <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiome</title>
          <description>Number of patients that experienced changes in the microbiome post FMT. Measured as similarity to the donor microbiome post FMT compared to their baseline sample</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over 2 years from June 2016 through May 2018</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With PSC</title>
          <description>This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.&#xD;
Fecal Microbiota Transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Patient had an infection that caused sinusitis and went to the ER to be treated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MIgraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jessica Allegretti</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177325500</phone>
      <email>jallegretti@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

